Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study

BACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to veri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajiev, Saur, Allara, Elias, Motedayеn Aval, Leila, Arizumi, Tadaaki, Bettinger, Dominik, Pirisi, Mario, Rimassa, Lorenza, Pressiani, Tiziana, Personeni, Nicola, Giordano, Laura, Kudo, Masatoshi, Thimme, Robert, Park, Joong-Won, Taddei, Tamar H., Kaplan, David E., Ramaswami, Ramya, Pinato, David J., Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852559/
https://www.ncbi.nlm.nih.gov/pubmed/33071284
http://dx.doi.org/10.1038/s41416-020-01116-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852559/
https://www.ncbi.nlm.nih.gov/pubmed/33071284
http://dx.doi.org/10.1038/s41416-020-01116-9

Ejemplares similares